Recent investigations have converged on the overlap of GLP-1|GIP|GCGR agonist therapies and dopamine neurotransmission. While GIP stimulators are widely employed for treating type 2 diabetes mellitus, their unexpected impacts on reward circuits, specifically governed by dopaminergic pathways, are receiving significant interest. This report presents